Skip to main content
. 2022 Sep 20;13:987639. doi: 10.3389/fimmu.2022.987639

Figure 3.

Figure 3

Characterization of plasma EVs from NSCLC patients during therapy. (A) Concentration and size distribution of EVs from R and NR patients, collected during ICI therapy, and heavy smokers (HS) healthy controls, using NTA (n = 8 per group). (B) Flow cytometric analysis of CD63, CD81, and CD9 EV markers during therapy on R and NR-EVs (R BL n = 13; R TP1 n = 4; NR BL n = 51; NR TP1 n = 7) (C) Surface EVs’ markers profiles determined by MACSPlex Exosome Kit in R and NR-EVs patients. The values are the median fluorescence intensities (R BL n = 8; R TP1 n = 6; NR BL n = 10; NR TP1 n=6). (D) Surface levels of of PD-L1, TIGIT, PD-L2 and VISTA in EVs collected pre- and after 1st treatment from R and NR patients (R BL n = 13; R TP1 n = 4; NR BL n = 51; NR TP1 n = 7). The data are expressed as the mean ± S.E.M. (*p < 0.05; **p < 0.01; ***0.001 < p < 0.0001).